DMAC vs NVO
DMAC: DiaMedica Therapeutics is a clinical-stage biotech developing recombinant kallikrein-1 and ulinastatin protein therapies for the treatment of ischemic conditions like preeclampsia and stroke. NVO: A global healthcare leader specializing in innovative treatments for diabetes, obesity, and other serious chronic conditions.
Side-by-side fundamentals
| Metric | DMAC | NVO | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $8.69 | $39.06 | |
| Market cap | $469M | $173.6B | |
| Net margin FY2025, SEC XBRL | n/a | +33.1% | |
| Gross margin FY2025, SEC XBRL | n/a | +81.0% | |
| Operating margin FY2025, SEC XBRL | n/a | +41.3% | |
| ROE FY2025, SEC XBRL | -58.4% | +52.8% | NVO higher |
| ROA FY2025, SEC XBRL | -53.4% | +18.9% | NVO higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +20.4% | |
| Dividend yield as of 2026-09-03 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 1.40 | 0.82 | |
| 1-year return as of 2026-10-21 close | +31.3% | -28.7% | DMAC higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.